First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer
Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone. Medscape Medical News …read more